Insider Selling: uniQure N.V. (NASDAQ:QURE) Director Sells 2,112 Shares of Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Leonard E. Post sold 2,112 shares of uniQure stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the sale, the director now directly owns 29,937 shares in the company, valued at $432,589.65. This represents a 6.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

uniQure Stock Down 2.8%

Shares of QURE traded down $0.40 during midday trading on Friday, reaching $13.83. The stock had a trading volume of 536,873 shares, compared to its average volume of 1,457,890. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The company's fifty day simple moving average is $14.51 and its two-hundred day simple moving average is $14.04. The company has a market cap of $757.55 million, a price-to-earnings ratio of -3.15 and a beta of 0.08. uniQure N.V. has a 1-year low of $3.73 and a 1-year high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. Equities research analysts expect that uniQure N.V. will post -3.75 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in QURE. Invesco Ltd. lifted its stake in uniQure by 453.2% during the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after purchasing an additional 502,684 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of uniQure during the 4th quarter worth approximately $320,000. Assenagon Asset Management S.A. lifted its position in shares of uniQure by 355.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after buying an additional 261,323 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of uniQure in the 4th quarter valued at $1,951,000. Finally, Northern Trust Corp grew its position in shares of uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after buying an additional 1,923 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

Analyst Ratings Changes

QURE has been the subject of several research reports. Wall Street Zen cut shares of uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a research report on Monday, May 19th. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research note on Thursday, May 29th. Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Finally, Chardan Capital restated a "buy" rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, uniQure currently has an average rating of "Moderate Buy" and a consensus target price of $37.82.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.